Additionally, in many younger patients, the stage of disease at the time of presentation is reportedly advanced and is seen to belong to more aggressive subtypes, e.g., triple-negative or human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.